Invuity, Inc. (NASDAQ:IVTY)‘s stock had its “buy” rating reiterated by equities researchers at Piper Jaffray Companies in a report released on Friday. They presently have a $12.00 target price on the medical instruments supplier’s stock. Piper Jaffray Companies’ price objective indicates a potential upside of 42.01% from the company’s current price.

Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Invuity from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. ValuEngine raised Invuity from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Northland Securities reissued a “buy” rating and set a $13.00 price target on shares of Invuity in a report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $11.67.

Invuity (NASDAQ:IVTY) traded up $0.20 during mid-day trading on Friday, reaching $8.45. The company had a trading volume of 109,900 shares, compared to its average volume of 48,369. Invuity has a fifty-two week low of $5.70 and a fifty-two week high of $9.70. The company has a current ratio of 2.90, a quick ratio of 2.63 and a debt-to-equity ratio of 5.39.

Invuity (NASDAQ:IVTY) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.04. The business had revenue of $9.60 million for the quarter, compared to analysts’ expectations of $9.87 million. Invuity had a negative return on equity of 212.38% and a negative net margin of 111.43%. analysts forecast that Invuity will post -2.4 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/12/invuity-inc-ivty-rating-reiterated-by-piper-jaffray-companies.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CAPROCK Group Inc. lifted its holdings in shares of Invuity by 28.6% during the 3rd quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 10,000 shares during the period. OxFORD Asset Management LLP bought a new position in shares of Invuity during the 2nd quarter valued at $374,000. B. Riley Financial Inc. bought a new position in shares of Invuity during the 2nd quarter valued at $3,625,000. Royce & Associates LP lifted its holdings in shares of Invuity by 141.9% during the 2nd quarter. Royce & Associates LP now owns 98,939 shares of the medical instruments supplier’s stock valued at $717,000 after buying an additional 58,033 shares during the period. Finally, FMR LLC lifted its holdings in shares of Invuity by 0.5% during the 1st quarter. FMR LLC now owns 829,564 shares of the medical instruments supplier’s stock valued at $6,595,000 after buying an additional 4,264 shares during the period. 66.01% of the stock is currently owned by hedge funds and other institutional investors.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.